top of page

About
- Our Company
- Our Leadership Team
Science
Products
Pipeline
Newsroom
Contact
Investors
More

Use tab to navigate through the menu items.

Newsroom

All Posts
Publication
News
Leadership Story

YD Bio and EG BioMed Launch AI Cancer Risk Assessment Tool Covering 10 Cancer Types

YD Bio and EG BioMed Launch AI Cancer Risk Assessment Tool Covering 10 Cancer Types

YD Bio and EG BioMed Launch AI Cancer Risk Assessment Tool Covering 10 Cancer Types

3 days ago

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

Sep 1

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

Aug 26

2 3 4 5

DNA Methylation

Investor Relations

Laboratory Developed Tests Services

Exosome Based Therapies

Clinical Trial Drug Distribution

Health Supplements

Privacy Statement

Data Rights Form

21720 23rd Dr. SE, Suite 275,

Bothell, WA 98021, USA

Email: info@ydesgroup.com

Tel: +1 (206) 888-0858

bottom of page